Awaiting development: Guidance and quality standards
Showing 251 to 260 of 389
| Title | Type |
|---|---|
| Povorcitinib for treating prurigo nodularis [GID-TA12018] | Technology appraisal guidance |
| Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720] | Technology appraisal guidance |
| Prevention of dementia | Quality standard |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| Primary hyperparathyroidism | Quality standard |
| Pritelivir (AIC-316) for Herpes simplex virus 2 infection (HSV-2) [12367] | Technology appraisal guidance |
| Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis | HealthTech guidance |
| ProKnow cloud-based system for radiotherapy data storage, communication and management | HealthTech guidance |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| Pulsed Field Ablation for Atrial Fibrillation | HealthTech guidance |